At day 4 after treatment start, we observed an increase in CD103+ Ly6C+ DCs in the secondary tumor of hRT/lena-treated mice compared to control mice, as well as lena and hRT monotherapy in the B16-OVA model (Figure 3A). The gene discussed is ITGAE; the disease is neoplasm.